Coronavirus: Chinese mRNA-based Covid-19 vaccines effective in preclinical trials

Two mRNA-based Covid-19 vaccine candidates produced by Chinese manufacturer CanSino Biologics have proven effective in preclinical trials, suggesting the potential for human tests, according to a new study published in the journal Emerging Microbes & Infections.

Results showed that the two vaccines, the mRNA-Beta and mRNA-Omicron, can induce high-tier neutralising antibody levels against original and multiple SARS-CoV-2 variants, such as Beta, Delta and Omicron.

Two doses of mRNA-Beta could induce broad protection, especially for the Beta and original variants. Meanwhile, mRNA-Omicron was suggested as a booster injection in mice vaccinated with primary mRNA-Beta or Ad5-nCoV, the company’s recombinant Covid-19 vaccine, to offer further protection against the Omicron variant, according to the study.

The Chinese mRNA vaccines got clinical trial approval in April and they have entered phase-1 human trials, according to a company statement released this week.

Compared with traditional vaccine technologies, the mRNA technology has the advantage of a shorter development and production cycle.

The Chinese vaccine maker said an industrialisation base of the Covid-19 mRNA vaccine was under construction in Shanghai. It will enable the annual production capacity to reach 100 million doses by the end of 2022.

ALSO READ:

• US: FDA staff says Moderna Covid-19 vaccine effective and safe for children

• Covid-19: New vaccine may be option for troops with religious concerns

• Newsletters